亚胺培南西司他丁钠联合环丙沙星治疗重症肺炎的临床效果及对血清C反应蛋白水平的影响

目的：研究亚胺培南西司他丁钠联合环丙沙星治疗重症肺炎患者的临床疗效以及对患者C反应蛋白（CRP）的影响。方法：将2019年5月－2020年5月接受治疗的72例重症肺炎患者作为本次研究对象，按照治疗方式将其分为2组，每组36例。对照组患者仅接受亚胺培南西司他丁钠进行治疗，观察组联合环丙沙星进行治疗，对比2组患者临床疗效差异以及对患者相关血清指标的影响差异。结果：观察组患者治疗总有效率（94.44%）明显高于对照组患者（80.56%）；观察组患者临床症状咳嗽、肺部啰音消失以及体温恢复的时间明显短于对照组患者（P<0.05）。治疗前2组患者血清指标PCT、IL-6及CRP和肺功能FEV₁、FVC以及PEF之间的差异均不明显（P>0.05），治疗后观察组患者血清指标明显更低，肺功能指标明显更高，与治疗前存在明显差异（P<0.05）；观察组患者产生头晕、胃肠道不适、皮疹以及身体疲劳等不良反应的总发生率（8.33%）明显低于对照组（19.44%）（P<0.05）。结论：亚胺培南西司他丁钠联合环丙沙星治疗重症肺炎患者具有良好的临床应用效果，对降低患者炎性因子，促进肺功能恢复，缓解患者临床症状以及减少不良反应具有明显作用。

Clinical effect of imipenem cilastatin sodium combined with ciprofloxacin in the treatment of severe pneumonia and its influenceon serum C-reactive protein level

OBJECTIVE To study the clinical efficacy of imipenem cilastatin sodium combined with ciprofloxacin in the treatment of severe pneumonia and its influence on C-reactive protein (CRP).METHODS 72 patients with severe pneumonia who were treated in our hospital from May 2019 to May 2020 were selected as the objects of this study,and they were divided into two groups according to the difference of treatment methods,with 36 cases in each group.The control group received imipenem cilastatin sodium alone for treatment,and the experimental group was treated with ciprofloxacin.The difference of clinical efficacy between the two groups and the influence on related serum indexes were compared.RESULTS The total effective rate of the observation group (94.44%) was significantly higher than that of the control group (80.56%);the time of clinical symptoms cough,lung rales disappearance and body temperature recovery in the observation group was significantly shorter than that in the control group (P<0.05).There was no significant difference in PCT,IL-6,CRP,FEV1,FVC and PEF in the two groups before treatment (P<0.05).After treatment,the serum indexes of the observation group were significantly lower,and the lung function indexes were significantly higher;there was significant difference between before and after treatment (P<0.05);the total incidence of dizziness,gastrointestinal discomfort,rash and physical fatigue in the observation group (8.33%) was significantly lower than that in the control group (19.44%),(P<0.05).CONCLUSION Imipenestatin sodium combined with ciprofloxacin has a good clinical effect in the treatment of patients with severe pneumonia,which has a significant effect on reducing inflammatory factors,promoting the recovery of pulmonary function,relieving clinical symptoms and reducing adverse reactions.